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InﬂammationInfection or cell damage triggers the release of pro-inﬂammatory cytokines such as interleukin(IL)-1α or β
and tumor necrosis factor (TNF)α which are key mediators of the host immune response. Following their
identiﬁcation and the elucidation of central signaling pathways, recent results show a highly complex
crosstalk between various cytokines and their signaling effectors. The molecular mechanisms controlling
signaling thresholds, signal integration and the function of feed-forward and feedback loops are currently
revealed by combining methods from biochemistry, genetics and in silico analysis. Increasing evidence is
mounted that defects in information processing circuits or their components can be causative for chronic or
overshooting inﬂammation. As progress in biosciences has always beneﬁtted from the use of well-studied
model systems, research on inﬂammatory cytokines may function as a paradigm to reveal general principles
of signal integration, crosstalk mechanisms and signaling networks.tsche Forschungsgemeinschaft
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Cytokines have been discovered almost half a century ago as small
proteins or polypeptides that orchestrate cellular communication. They
may act in an autocrine, juxtacrine, paracrine, endocrine or intracellular
fashion and can be grouped by common biological characteristics, as
summarized in Table 1. Pathogen-associated patterns (PAMPs) or
damage- or danger-associated molecular patterns (DAMPs) are sensed
by speciﬁc receptors. In turn, activation of these receptors leads to the
induced synthesis and release of inﬂammatory cytokines (interleukins
(e.g. IL-1, IL-6, IL-33), tumor necrosis factor (TNF)α, chemokines andmacrophage migration inhibitory factor (MIF). These cytokines coordi-
nate the host cell response in order to combat the infection [88], as
schematically displayed in Fig. 1A. PAMPs are generated fromproducts of
pathogenic microorganisms [133], while DAMPs are triggers for sterile
inﬂammation by endogenous mediators or exogenous stressors [22,87].
Cytokines are not produced and secreted fromdiscrete glands but can be
in principle produced by all nucleated cells to regulate the immune
response. Pro-inﬂammatory cytokines represent a paradigm for illus-
trating how basic research feeds in successful translational research. A
number of novel inﬂammatory cytokines have been discovered in recent
years (IL-32, IL-33, IL-34, IL-35, IL-36, IL-37) whose functions are being
explored at themoment [27,32,34,67,96,119,154]. On the other hand, the
“oldest” pro-inﬂammatory cytokines IL-1α, IL-1β and TNFα have been
studied in patients for quite some time [48] and antagonistic biologicals
are in clinical use (see below).
2. The importance of cytokine regulatory loops
Once cytokines have been released in response to initial signals
from PAMPs or DAMPs, they can bind to their own receptors and
thus help to potently amplify the innate immune response. Rapid
mounting of the immune response is absolutely essential to
counteract rapidly growing invading pathogens. Cytokine-triggered
signal ampliﬁcation employs several feed-forward signaling loops.
Once the infection has been cleared, the inﬂammatory process is
antagonized by strong negative feedback loops that ensure the
controlled shut-down of the immune response (Fig. 1A). Recent
Table 1
Functional classes of cytokines involved in inﬂammation (adapted from [32,35,97]. Blue colors indicate therapeutically used recombinant cytokines, purple colors indicate cytokines
for which inhibitory drugs have been approved. Abbreviations: CD40L, CD40 ligand; CNS, central nervous system; Gro, growth-related; IFN, interferon; IL, interleukin, IL-1Ra, IL-1
receptor antagonist; MCP1, monocyte chemotactic protein-1; MIF, macrophage migration inhibitory factor; MIP1α, macrophage inﬂammatory protein-1α; RANKL, receptor
activator of nuclear factor kappa-B ligand; Rantes, regulated upon activation, normal T-cell expressed; TGFβ, transforming growth factor beta; TNF, tumor necrosis factor.
functional class
cytokines regulating adaptive immune functions
lymphocyte growth and
differentiation factors
cytokines positively regulating innate immune functions
pro-inflammatory 
cytokines
chemokines
interferons
type II IFN
type I IFN
cytokines downregulating innate immune functions
anti-inflammtory
cytokines
pro-metastatic 
angiogenic
major physiological or pathophysiological effects
clonal expansion of T-cells,     Th1/TH2/TH17 
responses, Th1/Th2/Th17 polarization, B-cell activation, 
8-cell growth, auto-immune responses
    inflammatory mediators,    innate immune
responses,     activation of most cell types, pro
metastatic,     bone-resorption,     acute phase proteins 
    cellular emigration,     leucoyte infiltration, 
neovascularization,     activation of many cell types, 
macrophage activation,     MHC class II 
anti-viral,     MHC class I, anti-inflammatory, anti-
    inflammatory mediators,     cytokine-mediated
lethality,     autoimmune and autoinflammatory disease,
    fibrosis, anti-tumor effects
examples
IL-2, IL-4, IL-5, IL-6, IL-7, IL-12,
IL-15, IL-17, IL-18, IL-23, IL-25, IL-
33, IL-35, IFNγ
IL-1 α, IL-1 β, TNFα, IL-6, IL-12, IL-
18, IL-23, IL-32, IL-33, IL-34, IL-
36, MIF, CD40L, RANKL
IL-8 (CXCL8), MCP1 (CCL2), 
MIP1α (CCL3), Rantes (CCL5), 
Groα/β/γ (CXCL1,2,3), MIF, others 
IFNγ 
IFNα, IFNβ 
IL-10, IL-13, TGFβ, IL-22, IL-37
IL-1 Ra, IFNa/β
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feed-forward or of feedback loops can be causative for diseases. A
small number of patients with genetic defects in positive and
negative feedback loops in extracellular control of IL-1 have been
identiﬁed [3,4,36,106]. These patients develop systemic sterile
inﬂammation of varying severity. Constitutive activity of the
inﬂammasome complex which controls processing and release of
IL-1 results in periodic fever syndromes (Fig. 1B), whereas life-
threatening disease results from lack of negative control by the IL-1
receptor antagonist IL-1Ra (Fig. 1C/D). Even though this type of
positive and negative feedback control appears to be relatively
simple, it is of great pathophysiological relevance and underscores
the importance of studies on regulatory circuits in inﬂammatory
cytokine action.3. Levels of complexity of intracellular inﬂammatory
cytokine signaling
Research on signal transduction of inﬂammatory cytokines has
proceeded through several phases. The ﬁeld has moved from the
discovery of ligands, receptors and co-receptors (Fig. 2A) toward
identiﬁcation of complex cytosolic and nuclear signaling mechanisms.
For about a decade, the NF-κB, JNK (c-Jun N-terminal kinase), p38
MAPK (mitogen activated protein kinase), STAT (signal transducers
and activators of transcription) and PI3K (phosphatidylinositol-3-
kinase) pathways were viewed as separate “linear” cascades (Fig. 2B).
However, an emerging theme is that separated linear pathways do not
really exist. Rather, there is interconnected signaling at all levels of
intracellular signal transduction resulting in the concept of complex
signaling networks (Fig. 2C). This level of complexity by intracellular
signaling networks can be typically exempliﬁed by an IL-1 signaling
map which covers the canonical components of IL-1 signaling that are
used across various species [151]. It consists of 86 molecules involved
in at least 186 reactions as shown in Fig. 3.3.1. Modes of signal processing in inﬂammatory cytokine networks
Signal processing involves the study of pathways in which a
cellular signaling response is accelerated or dampened in form of
positive or negative feedback loops [122]. Multiple of these mecha-
nisms are joined to form a network enabling signal integration at
molecular, cellular and functional levels.
3.1.1. Signal integration at the molecular level
Positive and negative feedback mechanisms do not operate as
separated entities. Rather, they are intimately linked at multiple levels
by signal integration. This term refers to the phenomenon that two or
more pathways downstreamof a common receptor or effector converge
on the same signaling node. This signaling node can be any molecular
entity ranging from lipids or proteins to nucleic acids. Signal integration
occurs at the molecular level by means of multiple combinatorial post-
translational modiﬁcations such as phosphorylation, ubiquitination,
sumoylation, acetylation or ADP-ribosylation [12,25]. A typical example
for suchamolecular signal integration point serving as a signalinghub is
the MAP3K TAK1 (TGFβ-activated protein kinase 1), which receives
inputs from a plethora of upstream receptors [113,114,121] as shown
in Fig. 4A. TAK1 activation depends on TAB (TAK1-binding protein)
adaptor proteins 1–3which can bind to K63-linkedpolyubiquitin chains
and thus allows the transient recruitment of ubiquitinated partner
proteins that can activate TAK1. TAK1 further requires sequential
phosphorylation in its catalytic domain, but also the attachment of K63-
linked polyubiquitin chains by the E3 ligase TRAF6 for activation
[31,63,90,95,113,121,132,138,147,149,160]. Once assembled this way,
the TAK1–TAB complex determines the output signal and mediates
activation of NF-κB or the MAP2Ks MKK4 and MKK3/6 [156]. TAK1-
dependent NF-κB activation involves phosphorylation-dependent K48-
linked ubiquitination and subsequent degradation of IκBα (Fig. 4A).
Activation of NF-κB in response to pro-inﬂammatory cytokines or toll-
like receptor (TLR) agonists also requires ubiquitination of NEMO
(NF-κB essential modulator), a regulatory subunit of the IκB kinase
Fig. 1. Deregulation of cytokine loops as a major cause of inﬂammatory diseases. A) The discovery of IL-1β [9] revealed a major role of these cytokines in innate immune reactions in
response to infection (PAMP signals) or damage (DAMP signals) [33,36]. Itwas also found that IL-1 induces its own expression as a positive feed-forward loop [40] aswell as expression of
its antagonist IL-1Ra in a negative feedback loop during inﬂammatory reactions [47]. A sophisticated balance between IL-1β release and counter-acting IL-1Ra levels suppresses
spontaneous inﬂammation, but also ensures correct termination of IL-1-dependent inﬂammation [37,39]. B) Discovery of an IL-1-processing multi-protein complex (called
inﬂammasome) and identiﬁcationofpatientswith gain-of-functionsmutations in inﬂammasomeproteins revealedanumberof auto-inﬂammatorydiseases thatare drivenbyexcess IL-1β
production as a result of dominant positive feed-forward loops. As symbolized by the thickness of the arrows and by additional arrows, the spontaneous release of preformed IL-1β
overrides the balance of systemic IL-1β and IL-1Ra [85,86]. C) Recently, a fewpatientswere identiﬁed that lack the IL-1Raprotein due to frame-shiftmutations or genedeletions [4,37,106].
As shown, this lack of negative feedback control results in life-threatening systemic inﬂammation and osteopathy due to spontaneously released IL-1β (and IL-1α, not shown). D) The
clinical features of patients with genetic deletion or mutation of the IL-1Ra comprise sterile pustulosis and skin inﬂammation (a, b), massive epiphyseal ballooning of long bones (c),
radiographically visible enlargement of ribs and clavicles (d), ossiﬁcation of the proximal femoral metaphysis and periosteal elevation of the diaphysis (e), and an osteolytic lesionwith a
sclerotic rim (f). Fig. 3D and the information described in the legend was reproduced with permission from [4] and the New England Journal of Medicine.
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balance of signal integration at the level of the TAK1–TAB or IKK–NEMO
complexes can result in skin inﬂammation, liver inﬂammation, ﬁbrosis
and cancer [11,58,118]. Downstream of TAK1–TAB and IKK–NEMO, the
NF-κB subunit p65 is also a prominent example of signal integration at
the molecular level. Nuclear activity of p65 is regulated by multiple
phosphorylations, polyubiquitination and acetylation [23,45,98,108]
and Fig. 4A. Many viral proteins hijack signal integrators in order to
manipulate central cellular functions, thus supporting the idea that
signal integrators are of major relevance for the coordination of
signaling events. This also applies to the TAK1/TAB1 complex, which is
for example activated by the T cell leukemia virus type 1 (HTLV-1) Tax
protein [153], by Kaposi's sarcoma-associated herpes virus (KSHV) G
protein-coupled receptor (vGPCR) protein [14], or by latent membrane
protein 1 of Epstein–Barr virus [142,148]. Signal integration also occurs
at functional levels. A very prominent example is the upregulation of
mRNAs during pro-inﬂammatory cytokine responses. Triggers such as
IL-1, TNFα or LPS induce mRNA expression of secondary inﬂammatory
mediators (e.g. IL-6, IL-8, cyclooxygenase 2) by simultaneously
activating transcriptional and post-transcriptional pathways. Within
the nucleus, this is provided by co-ordinated recruitment of transcrip-
tion factors and co-activators in concert with chromatin-relaxingmechanisms at the level of gene promoters (reviewed in [89]). Many
of these mRNAs bind destabilizing proteins in the cytoplasm and are
maintained at low steady-state levels by sequential deadenylation,
decapping and RNA-degradation [18]. Other cytokine mRNAs are kept
translational silent probably by directing these molecules to particles,
where ribosome-mediated protein biosynthesis is blocked. Efﬁcient
gene responses during inﬂammation thus require stabilization ofmRNAs
and translational derepression by signal-mediated processes through the
p38–MK2-pathway [44]. The importance of these pathways can be
deduced from the phenotype of mice lacking destabilizing proteins such
as tristetraproline (TTP). These mice display enhanced inﬂammatory
cytokine expression and systemic inﬂammation [52,135]. However, the
components of post-transcriptional cytokine pathways, their subcellular
localization, regulation by post-translational modiﬁcations and role in
translation as well as their interplay with transcriptional pathways are
still not completely understood (reviewed in [7,8]).
3.1.2. Positive feed-forward loops
Feed-forward loops proceed through several signaling intermedi-
ates to provide sustained or elevated stimulation of a response. Such
powerful feed-forward loops are needed to amplify the immune
response in order to antagonize the logarithmic growth of pathogens.
Fig. 2.Milestones of research on inﬂammatory cytokine signaling. (A) IL-1 family members and receptors were discovered more than 25 years ago [9,80,123]. (B) Research on signal
transduction during the last decade has focussed on the concept of linear cascades primarily resulting in the activation of NF-κB, JNK, p38, ERK, STAT and PI3 kinase pathways
(reviewed in [16,33,44,54,73,84]. (C) The current view describes a multitude of interactions and post-translational modiﬁcations interconnecting all known pathway components
forming large signaling networks as shown in Fig. 3.
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inﬂammatory response including autocrine and paracrine feedfor-
ward and ampliﬁcation loops. For example, many inﬂammatory
cytokines such as IL-1β or TNFα promote the expression of their own
genes (Fig. 4B), or LPS-induced secretion of TNFα, thus mediating
autocrine NF-κB activation and ampliﬁcation of pro-inﬂammatory
signaling [29]. Other examples of this kind of signaling are the TNFα-
induced induction of type I interferons [158] or the IL-1-induced
secretion of IL-8 [83] which boost TNFα-or IL-1-responses, respec-
tively (Fig. 4C). While IL-1, TNFα and LPS share many signaling
components, the TNFα-induced IFN induction is also an example of
crosstalk (see below), because IFNs signal through distinct JAK-STAT
pathways [44]. This situation is similar for IL-8, which signals through
G-protein-coupled CXCR1/2 chemokine receptors [150], as displayed
in Fig. 4C).
3.1.3. Negative feedback loops
Many signals of the induction phase already initiate a default
termination program that allows a temporally and spatially well-
controlled deactivation of the inﬂammatory response by negative
feedback loops. Multiple cellular and molecular mechanisms ensure
the resolution of inﬂammation, including the production of anti-
inﬂammatory cytokines such as IL-1Ra, IL-10, TGF-β and IL-37, as
schematically shown in Fig. 4D. The clearance of inﬂammation also
involves further mechanisms such as the switch from prostaglandins/
leukotriens to anti-inﬂammatory lipoxins and the elimination of
neutrophils by apoptosis [92,93]. At the level of intracellular signaling,
this default termination program is exempliﬁed by the stereotypical
pro-inﬂammatory transcription factor NF-κB, which is deactivated by
multiple mechanisms including the NF-κB-induced synthesis of the
inhibitory IκB proteins (Fig. 4D) [53,105,131,155]. While IκBα
terminates the fast NF-κB response, the late NF-κB activity is
antagonized by proteins such as A20 [120], Cyld [17,72,141] and
COMMD1 [45] (Fig. 4D). The latter is an example of a novel
mechanism in signal termination as it involves degradation of p65
on speciﬁc promoters [134]. Proteolytic mechanisms to destroy hostFig. 3. Regulatory loops, feed-forward and feedback mechanisms in the canonical IL-1 sig
schematic visualization of the canonical IL-1 signaling network as published in ref. [151].
references and can be accessed at (http://stke.sciencemag.org/cgi/cm/stkecm;CMP_21286).
post-translational modiﬁcations and cellular translocations of signaling components are spe
and green boxes decision points in intracellular signaling were connected by logical operato
CellNetAnalyzer [68,69]. This network forms a basis for future network reconstruction by mcell signaling effectors have also been adopted by certain bacterial
proteases such as the NleC Protein of pathogenic Escherichia coliwhich
cleaves p65 [159] but also JNK [10].
Inappropriate termination of NF-κB activity can be causative for
chronic inﬂammation and several ailments ranging from rheumatoid
arthritis (RA) to inﬂammatory bowel disease (IBD). Defect termina-
tion might be due to gene mutations for the proteins mediating the
negative feedback loops or to defect signaling circuits that serve to
wind down NF-κB activity [144]. The RNA-destabilizing protein
tristetraproline is not only an inducible negative regulator which
reduces mRNA steady state levels [15,20,52,74,82] but which also
interacts with and negatively regulates NF-κB [78,116]. Most of the
negative regulators in the NF-κB system are inducibly expressed
[107]. Likewise, activation of the MAPKs JNK and p38 which occurs in
parallel to activation of the NF-κB pathway is switched off by
inducible expression of MAPK-speciﬁc phosphatases such as MAPK
phosphatase 1 (MKP-1) [1,2,24,25,62,64,79,161] and Fig. 4D. The
importance of negative feedback loops and mechanisms that control
the thresholds of signaling is mainly derived from mouse models but
also from genetic polymorphisms observed in humans. A recent
survey of loss-of-function phenotypes listed 81 genes whose
mutations lead to spontaneous emergence of persistent inﬂammation
in humans living in normal conditions or in standard laboratory mice
without a known evident autoimmune or inﬂammatory insult [93].
Thus, it takes a highly co-ordinated response of 81 (or more) genes to
suppress spontaneous inﬂammation. All observations cited above
suggest that the true number of anti-inﬂammatory genes is not
known yet and will likely be much higher. It can be concluded that
spontaneous inﬂammation may arise whenever there is a loss of a
non-redundant component or of a mechanism that regulates
proliferation or signaling in lymphoid, myeloid, or epithelial cells
responding to antigens, microbes, or injury [49,81,88,92,124]. The
mediators and molecular mechanisms employing these important
signal processing events are incompletely understood and the
number of regulators and reactions involved raises the need to
combine experimental data with in silico pathway building.naling network. The software PathVisio [65,104,143] was used to draw a structured
The evidence for each interaction between signaling components was taken from 469
In the depicted map activating feed-forward and inactivating feedback loops, important
ciﬁcally highlighted as indicated in the legend box. In addition, as shown by blue circles
rs to visualize the information ﬂow through the signaling system by using the program
athematical modeling (see text for details).
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Fig. 4. Prototypical mechanisms of regulatory loops, crosstalk and signal integration in cytokine pathways. The concepts are schematically shown and the effects on signal strength or
the on-off status are given in the legend. Abbreviations: COMMD1, copper metabolism (Murr1) domain containing 1; Cyld, cylindromatosis; COX-2, cyclooxygenase 2; Gαβγ, small G
proteins; IL-1R, IL-1 receptor; PG, prostaglandin; TNFR, TNF receptor.
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Mutual inﬂuences of signals generated from different pathways are
referred to as crosstalk. This crosstalk occurs at all levels: between
different inﬂammatory cells, cytokines and also intracellular signaling
pathways. At themolecular level, there is recent evidence for crosstalk of
“canonical”NF-κB/MAPKsignalingwith “non-canonical” tyrosine kinase
pathways [44]. Other examples are the modulation of inﬂammatory
gene expression by circadian clock pathways [66] or by prostaglandin-
cAMP-PKA (protein kinase A) pathways [13,46,56,70,140,146] and
Fig. 4C). Further examples are the peroxisome proliferator-activated
receptor beta/delta (PPARβ/δ)-mediated inhibition of IL-1 signaling
[26], the induction of TH2 cytokines by IL-1 and STAT5 activation [51],
or the epidermal growth factor (EGF)-mediated inhibition of TNFα-
signaling [60]. The extentof crosstalk during inﬂammation is notknown,
but these few examples emphasize the need to imply and to study the
inﬂuence of other pathways on basal and inducible activation states of
inﬂammatory cytokine signaling pathways.
4. In silico reconstruction of inﬂammatory cytokine
signaling networks
As evident from the arguments raised above, all mechanisms in
inﬂammatory signaling act in an integrated fashion to form a biological
signalingnetwork. Signalingnetworks surveyenvironmental conditions
andmake decisions to adapt cellular behavior. They convey information
distinguishing them frommetabolic networks, which convert extracel-
lular material or recycle and dispose intracellular materials [57].
Signaling networks are built from components (proteins, nucleic
acids, lipids) and their interactions. In a kind of retrograde approach a
few inﬂammatory subnets have been delineated from transcriptome or
proteome data sets [21,55,137,157]. However, a more sophisticated
approach is to transfer current mechanistic knowledge into computer
models, a process which is called signal network reconstruction.
Reconstruction of signaling networks requires the generation ofcarefully curated databases for warehousing available information on
components and their interactions. It also needs tools for mapping,
organizing and visualizing data base information and appropriate
algorithms for mathematical analyses and network reconstructions.
Mathematical modeling then allows to describe and analyze network
functionally, or, to predict gaps andmissing components or interactions
[102,111]. This can be achieved quantitatively by stoichiometric
approaches [101,103]. Alternatively, Boolean approaches can be used
which utilize sets of active or inactive components connected by logical
operators [69]. The latter approach is better suited for large networks
and does not require quantitative information on component concen-
trations, modiﬁcations and reaction parameters [57].
At presentno comprehensive signaling network reconstruction of an
eukaryotic cell has been achieved [57]. The largest network consists of
909 components and 752 interactions [77] andwas adapted fromamap
of toll-receptor signaling [99]. This network does not involve RNA
components, such as target mRNAs, micro-RNAs or other non-coding
RNAs, whichmay alsomodulate signals atmany steps. Next-generation
sequencing [91] will facilitate the genome-scale assessment of coding
and non-coding RNA constituents in available networks. Information on
regulated mRNA transcripts and RNA components of ribonucleoprotein
complexes is needed to expand the existing knowledge contained in
available inﬂammatory cytokine pathways.
Another example for a reconstructed network is the recently
published map of IL-1 signaling components that was generated by
reviewing 25 years of research on IL-1 which resulted in a manually
curated data base containing approximately 500 carefully selected
publications. The largest version at present incorporates information
on 237molecules and 564 reactions (A.Weber, P.Wasiliew, M. Kracht,
unpublished data). The canonical part of the IL-1 signaling network
contains 86 molecules and 189 interactions representing the core
pathways, which are activated by the cytokine in many different cell
types of mice andmen [151]. A graphic representation of this network
highlighting post-translational modiﬁcations, changes in subcellular
localization and regulatory loops is shown in Fig. 3. We have started to
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a logical model by setting up Boolean equations (unpublished data)
for all connecting edges and nodes of the map using CellNetAnalyzer
[68,69]. The main nodes and operator settings have been super-
imposed on the map graphically as shown in Fig. 3. The underlying
equations will facilitate computation of signaling network responses
which can then be experimentally validated. In the long term, such
reconstructed networks can be reﬁned by a mutual process of virtual
prediction and experimental veriﬁcation to reﬂect as faithfully as
possible the biological situation.
By the example described above, this overview displays the
enormous complexity of signaling pathways that requires in silico
analysis tools for the visualization of networks and the design of
experiments to test experimental predictions.
There are only a few other networks of this type which, however,
contain less information [5,19,59,61]. It can be concluded that
reconstruction of inﬂammatory cytokine networks is still in its infancy
and requires comprehensive analysis of protein and RNA components,
expert-curated assessment of their interactions and network recon-
struction by mathematical modeling.
5. Cytokines in the clinics
Frequently, attempts to apply recombinant inﬂammatory cytokines in
vivo led to intolerable systemic side effects, as exempliﬁedby IL-1 [94,125]
or TNFα [30,117] which cause fever, nausea, and hypotension. However,Fig. 5. Physiological and pathological malfunctions of intracellular cytokine networks—optio
conditions, inﬂammatory signaling is suppressed by dominance of constitutively expressed
inﬂammation a rapid, boost-like response is initiated by the co-operative action of positive
rapid subsequent termination of signaling and the systems eventually returns to the off-sta
products act as negative regulators at multiple levels of the signaling network. Mutation or
exogenous triggers. In the depicted example TTP is missing. (D) Chronic inﬂammation may a
disturbed by ﬂuctuations in activity of signaling molecules resulting in a maintained “on” st
increased or reduced activity and the inﬂammatory phenotype is indistinguishable from thTNFα has found a niche for localized treatment of soft tissue sarcoma and
melanoma by isolated limb perfusion in combinationwith chemotherapy
[50]. Only a limited number of other cytokine family members can be
routinely used in the clinic (e.g. erythropoietin, G-CSF, GM-CSF, IFNβ,
IFNγ). In contrast, protein-based drugs antagonizing individual cytokines
or their receptors (antibodies, cytokine-traps) are much better tolerated
than recombinant cytokines [35,41,42,100,112,115,130,136,145].
The largest group of these drugs targets pro-inﬂammatory cytokines.
Since 1999, ﬁve agents directed against TNFα (Inﬂiximab, Etanercept,
Adalimumab, Golimunab, Certolizumab) and three agents neutralizing
the effects of IL-1α and IL-1β (Anakinra, Canakinumab, Rilonacept)
have been used to treat hundreds of thousands of patients suffering
from diseases ranging from rare febrile syndromes (Muckle–Wells
disease, neonatal-onset-multi-inﬂammatory disease) to common
conditions such as rheumatoid arthritis, chronic IBD, psoriasis, gout
[44,109,126] or even diabetes [76]. However, all antibodies and
cytokine-traps currently in use do not cure chronic inﬂammatory
diseases as symptoms re-occur immediately once therapy is ceased
[38,71,93]. Moreover, one to two thirds of patients do not respond,
loose response during therapy or develop non-tolerable side-effects
[6,28,43,48,110]. Apart from this, protein-based drugs impose a heavy
economic burden on society as they are very expensive [129].
Thus, there is an urgent need for identifying additional principles and
targets to control cytokine action during disease [44,97]. Certainly, a
better understanding of cytokine signaling networks is one of the
prerequisites to achieve these goals.ns for multiple disturbances which can all result in chronic inﬂammation. (A) In healthy
negative regulators which ensure an efﬁcient “off” state of the system. (B) In “normal”
feed-forward signals. The parallel increased expression of negative regulators ensures
te. (C) As outlined in Ref. [93], at least 80 different genes have been identiﬁed whose
deletion of any of them results in “stereotypic” chronic inﬂammation in the absence of
lso arise in the absence of exogenous triggers under conditions where the signal ﬂow is
ate. In this scenario, no genetic alterations are observed, but signaling proteins display
e situation in (C).
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The inﬂammatory process is characterized by the co-ordinated
release of many different cytokines that are used by cells to orchestrate
immune and other complex responses. In the last decade it has become
very clear that this enormous complexity is mirrored at the level of
intracellular signal transduction. Apparently, evolution has generated
signaling systems that are robust, because they are backed-up at
multiple levels. At the same time thenetwork architecture ensures rapid
“switch-like” ampliﬁcation of immune responses, but also their faithful
terminations. The understanding of the underlying mechanisms of
signal processing, signal integration and crosstalk is still in its infancy.
Much insight has been derived by studying principles, mechanisms,
regulation and overall consequences of signal transmission by cytokines
in model systems that can be manipulated and analyzed in a
quantitative manner. However, it will be equally important to study
components, their post-translational modiﬁcations and their activity
states in human individuals.Moreover, aswe are dealingwith networks,
methods need to be developed to study and analyze as many signaling
components as possible in individual patients. Antibody arrays or
proteomics methods suiting this purpose have been developed; but
unlike the analyses of nucleic acids, the comprehensive analyses of the
regulatory proteome is far from being routine. However, at this point it
can be speculated that sterile inﬂammation of any kindmay be found in
patientswith no apparent abnormalities in the genes encoding negative
or positive signal regulators. This scenario is schematically displayed
in Fig. 5D, where such a situation is compared to other (patho)
physiological situations of inﬂammatory gene expression (Fig. 5A–C). In
this case, some kind of aberrant information ﬂow may be maintained
and might prevent resetting of signaling networks into their normal
inactive state. Such events may happen stochastically, or as a result of
slight, but cumulating ﬂuctuations and disturbances of correct protein
functions in space and time. In this case, there may be no “trackable”
cause of sterile inﬂammation at the genetic level. Finally, we all know
how easily computer programs break down, even though the hardware
is perfectly ﬁne. Searching for such “software” failures in inﬂammation
remains one of the most interesting and challenging tasks for future
research.
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